Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis

IMPORTANCE: As disease-modifying treatment options for multiple sclerosis increase, comparisons of the options based on real-world evidence may guide clinical decision-making. OBJECTIVE: To compare the relapse outcomes between 2 pairs of disease-modifying treatments: dimethyl fumarate vs fingolimod...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jue, Kim, Nicole, Cai, Tianrun, Dahal, Kumar, Weiner, Howard, Chitnis, Tanuja, Cai, Tianxi, Xia, Zongqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596196/
https://www.ncbi.nlm.nih.gov/pubmed/34783826
http://dx.doi.org/10.1001/jamanetworkopen.2021.34627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596196/
https://www.ncbi.nlm.nih.gov/pubmed/34783826
http://dx.doi.org/10.1001/jamanetworkopen.2021.34627

Ejemplares similares